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Abstract The islet-speci¢c glucose-6-phosphatase-related pro-
tein (IGRP) has no known catalytic activity, but is of interest
because it is the source of the peptide autoantigen targeted by a
prevalent population of pathogenic CD8þ T cells in non-obese
diabetic mice. To better understand the potential roles of this
protein in diabetes mellitus, we examine the subcellular local-
ization and membrane topography of human IGRP. We show
that IGRP is a glycoprotein, held in the endoplasmic reticulum
by nine transmembrane domains, which is degraded in cells
predominantly through the proteasome pathway that generates
the major histocompatibility complex class I-presented peptides.
+ 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The glucose-6-phosphatase (G6Pase) family is composed of
three proteins: G6Pase-K [1,2], G6Pase-L, also known as ubiq-
uitously expressed G6Pase-related protein [3^5], and IGRP,
the islet-speci¢c G6Pase-related protein [6,7]. IGRP was ini-
tially identi¢ed by its V50% amino acid sequence identity to
G6Pase-K as a putative islet-speci¢c phosphohydrolase [6,7].
Given the critical role of G6Pase-K in the control of blood
glucose homeostasis between meals [8,9], the discovery of
IGRP appeared to provide a missing link between G6Pase
activity and diabetes. But despite sharing the same active
site structure as G6Pase [8], IGRP fails to exhibit phosphohy-
drolase activity and had appeared to be an inactive member of
the G6Pase family [6,7]. Recently, however, Lieberman and
coworkers [10] revived interest when they identi¢ed IGRP
amino acids 206^214 as a source of the nonapeptide recog-
nized by a prevalent population of pathogenic CD8þ T cells in
non-obese diabetic (NOD) mice [11], a model of type 1 dia-
betes [12]. We have now investigated if IGRP is, as its homol-
ogy suggests, a multiple transmembrane domain endoplasmic
reticulum (ER)-associated protein, with an intact active site
facing into the ER lumen, or whether there is something dif-
ferent between IGRP and G6Pase that can explain the lack of
activity yet its unique role in diabetes.
We show that IGRP is localized physically within the mem-
branes of the ER. Using protease protection and glycosylation
scanning experiments we demonstrate that IGRP is a glyco-
protein anchored in the ER by multiple transmembrane heli-
ces and oriented in a similar manner to G6Pase-K [13,14] with
the N-terminus in the lumen of the ER and the C-terminus in
the cytoplasm. Of the three potential Asn-linked glycosylation
sites, only the site at amino acids 92^94, situated in the large
luminal loop 1, is glycosylated, consistent with the ‘active site’
being oriented inside the ER lumen. Processing of IGRP is
also shown to proceed via the proteasome [15^17], an intra-
cellular proteolytic pathway that generates antigenic peptides
presented by the major histocompatibility complex (MHC)
class I molecules [18].
2. Materials and methods
2.1. Isolation of human IGRP cDNA and construction of IGRP
mutants
The coding region of human IGRP was isolated by reverse tran-
scription polymerase chain reaction (PCR) ampli¢cation of human
pancreas mRNA (Invitrogen, Carlsbad, CA, USA) using oligonucleo-
tide primers derived from nucleotides 1^18 (sense) and 1049^1068
(antisense) of human IGRP mRNA [7]. The PCR product was cloned
into the pSVL vector and veri¢ed by DNA sequencing. Human IGRP
containing an N- or C-terminal FLAG (DYKDDDDK) tag was con-
structed as previously described [13] using IGRP as a template.
Human IGRP containing a C-terminal FLAG (IGRP-3FLAG) was
used as a template for the construction of glycosylation mutants. The
sense and antisense mutant primers were: N50A (nucleotides 136^
162), AAT to GCT at position 50; N92A (nucleotides 262^288),
AAT to GCT at position 92; N287A (nucleotides 850^870), AAC
to GCC at position 287. The human G6Pase-3FLAG cDNA has
been described [13].
2.2. Immuno£uorescence microscopy
COS-1 cells were grown at 37‡C in HEPES-bu¡ered Dulbecco’s
modi¢ed minimal essential medium supplemented with 4% fetal bo-
vine serum. Cells (5U104/chamber) in two-well-chambered cover-
glasses (Nalge Nunc International, Naperville, IL, USA) were trans-
fected with 2 Wg of IGRP-3FLAG or G6Pase-3FLAG construct, in
the pSVL vector, using SuperFect transfection reagent according to
the manufacturer’s protocol (Qiagen, Valencia, CA, USA). After in-
cubation at 37‡C for 2 days, the transfected cells were ¢xed on the
coverglass for 10 min at 25‡C in 3.7% formaldehyde in phosphate-
bu¡ered saline (PBS).
For intracellular staining, the cells were blocked with 2% normal
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horse serum in PBS for 20 min at room temperature, incubated with a
monoclonal anti-FLAG antibody (Sigma, St. Louis, MO, USA) in
PBS containing 0.1% saponin for 1 h, followed by goat £uorescein
isothiocyanate (FITC)-conjugated anti-mouse IgG (Sigma) in PBS
containing 0.1% saponin for 1 h. Following washing in PBS contain-
ing 0.1% saponin, the cells were ¢nally mounted with an anti-fade,
water-based mounting medium (Vector Lab, Burlingame, CA, USA)
and analyzed under a laser scanning confocal £uorescence microscope
(Leica TCS-4D DMIRBE, Heidelberg, Germany). Staining of the
calreticulin ER marker [19] was performed similarly using rabbit
anti-calreticulin antibody (A⁄nity BioReagents, Golden, CO, USA)
and tetrarhodamine isothiocyanate (TRITC)-conjugated goat anti-
rabbit IgG (Sigma). Excitation wavelengths of 488 (for FITC), and
568 (for TRITC) nm were used to generate £uorescence emission in
green and red respectively. Co-localization of green £uorescent IGRP
or G6Pase and red £uorescent calreticulin is re£ected by yellow £uo-
rescence.
2.3. Protease protection and Western blot analyses
COS-1 cells in 25-cm2 £asks were transfected with 10 Wg of either
IGRP-5FLAG or IGRP-3FLAG, in the pSVL vector as previously
described [13]. After incubation at 37‡C for 2 days, cell homogenates
in 100 Wl of bu¡er A (0.25 M sucrose and 5 mM HEPES, pH 7.4)
were treated with 250 Wg/ml DNase I for 30 min at 30 ‡C, followed
with trypsin (type XIII, 500 Wg/mg protein) for 30 min at room tem-
perature. Then, phenylmethylsulfonyl £uoride (¢nal concentration of
5 mM) and trypsin inhibitor (¢nal concentration of 6 mg/mg protein)
were added to inactivate trypsin. The resulting digests were diluted
100-fold with cold bu¡er A and centrifuged at 100 000Ug for 1 h at
4‡C to pellet the microsomes. The microsomal pellets were resus-
pended in bu¡er A for Western blot analysis. As controls, cell homo-
genates were prepared as described above, with the addition of 0.5%
deoxycholate to disrupt the microsomes.
For Western blot analysis of FLAG-tagged IGRP, proteins in
transfected COS-1 lysates were separated by electrophoresis through
a 12% polyacrylamide^sodium dodecyl sulfate gel, blotted onto poly-
vinylidene £uoride membranes (Millipore, Bedford, MA, USA), incu-
bated with a monoclonal antibody against the FLAG epitope and the
antigen^antibody complex visualized as described previously [4].
3. Results
3.1. IGRP is localized in the ER
To determine the subcellular localization of IGRP, a
FLAG-tagged construct of IGRP was transfected into COS-
1 cells and visualized by double immunostaining of the IGRP
and calreticulin [19], an ER marker protein. IGRP co-local-
ized with calreticulin, with no plasma membrane staining (Fig.
1), con¢rming that IGRP is retained within the ER of the cell.
As expected, G6Pase-K also co-localized with calreticulin (Fig.
1).
3.2. Membrane topography of IGRP
Since ER microsomes are closed vesicles with de¢ned cyto-
plasmic and luminal surfaces [20], protease protection assays,
using epitope-tagged constructs, can identify the cytoplasmic
or luminal exposure of the protein’s N- and C-termini and
reveal whether there are an even or odd number of transmem-
brane domains. Intact microsomes, isolated from IGRP-
5FLAG- or IGRP-3FLAG-transfected COS-1 cells, were sub-
jected to digestion by trypsin and the presence of the FLAG
epitope was visualized by Western blot analysis. The FLAG
tag of IGRP-5FLAG-transfected cells was resistant to trypsin
digestion while the FLAG tag of IGRP-3FLAG-transfected
cells was cleaved by this protease (Fig. 2A). In parallel experi-
ments in which the microsomes were permeabilized by deter-
gent, both N- and C-terminal FLAG tags were cleaved by
trypsin (Fig. 2A). Therefore the N- and C-termini of IGRP
Fig. 1. IGRP is localized in the ER. Double immuno£uorescence staining for recombinant IGRP (green £uorescence), recombinant G6Pase-K
(green £uorescence), and endogenous calreticulin (red £uorescence) in COS-1 cells expressing human IGRP-3FLAG or human G6Pase-K-
3FLAG. Note the intracellular co-localization of IGRP or G6Pase-K with the ER marker calreticulin, indicated by yellow in the merged image.
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are on opposite sides of the microsomal membrane and there
must be an odd number of transmembrane domains.
3.3. Human IGRP contains nine transmembrane helices
Based on its homology to G6Pase-K, IGRP can be ¢tted to
a nine-transmembrane helical structure (Fig. 3). However,
other theoretical modeling, using the TMpred program [21]
predicts that both human and mouse IGRP could be an-
chored in the ER by seven putative transmembrane helices.
Glycosylation analysis can di¡erentiate these models. IGRP
contains three consensus sequences for Asn-linked glycosyla-
tion at residues 50^52 (N50QT), 92^94 (N92HS), and 287^289
(N287YT) (Fig. 3). The seven-transmembrane model of IGRP
[21] predicts that N50QT, residing within the 56-residue N-
terminal domain, is the only site that can be glycosylated
[22,23]. In contrast, the nine-transmembrane model of IGRP
predicts that N92HS, situated within the 37-residue luminal
loop 1, is glycosylated (Fig. 3). We therefore constructed three
IGRP-3FLAG-tagged mutants, each disrupting one of the
Asn-linked glycosylation consensus sequences, transfected
COS-1 cells and analyzed the biosynthesis of IGRP, in the
absence or presence of tunicamycin [24], by Western blot.
The wild-type IGRP-3FLAG construct is expressed as poly-
peptides of 42 kDa and 39 kDa in the absence tunicamycin
Fig. 2. IGRP is a nine-domain transmembrane protein. A: Sensitivity of N- and C-termini of human IGRP to proteolytic digestion. Intact mi-
crosomes isolated from IGRP-5FLAG- or IGRP-3FLAG-expressing COS-1 cells were subjected to digestion by trypsin in the absence or pres-
ence of deoxycholate as described in Section 2. The IGRP proteins on the Western membrane were visualized by an anti-FLAG monoclonal
antibody; each lane contained 20 Wg proteins. B: Western blot analysis of wild-type and mutant IGRP synthesis. COS-1 cells were transfected
with 3FLAG-tagged wild-type or mutant IGRP construct in the absence or presence of tunicamycin (1 Wg/ml) as described in Section 2. The
IGRP proteins on the Western membrane were visualized by an anti-FLAG monoclonal antibody; each lane contained 20 Wg proteins.
Fig. 3. The predicted nine-transmembrane helical structure of human IGRP. The transmembrane helices are identi¢ed based on sequence and
topographical similarities to G6Pase-K [13,14]. Amino acid residues predicted to comprise the active center are denoted by large black circles.
The Asn-linked glycosylation site at residues 92^94 that acts as an acceptor for oligosaccharides, and amino acids at 206^214 corresponding to
the natural peptide antigen are highlighted.
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and as a single polypeptide of 39 kDa in the presence of
tunicamycin (Fig. 2B), consistent with the Asn glycosylation
of human IGRP. When mutated, the N50A and N287A con-
structs are also expressed as 42-kDa/39-kDa polypeptides in
the absence of tunicamycin and as a 39-kDa polypeptide in the
presence of tunicamycin (Fig. 2B), consistent with the pattern
of the native construct. Therefore N50QT and N287YT are not
sites of glycosylation. In contrast, the N92A construct is only
expressed as a 39-kDa polypeptide in the absence or presence
of tunicamycin (Fig. 2B), consistent with N92HS being the site
of glycosylation and supporting the nine-transmembrane do-
main model.
3.4. The proteasome inhibitor lactacystin induces the
accumulation of IGRP
If human IGRP is degraded in cells predominantly through
the proteasome pathway [15^17], turnover of the protein
should be inhibited by the proteasome inhibitor lactacystin
[25,26]. In the absence of lactacystin IGRP-transfected COS-
1 cells express the 42-kDa glycosylated IGRP two-fold more
abundantly than the 39-kDa non-glycosylated IGRP (Fig. 4).
In the presence of lactacystin, the steady-state levels of both
forms of IGRP increase, although unequally, with both forms
being expressed at equivalent levels, suggesting that the 39-
kDa non-glycosylated IGRP is normally less stable than the
processed form.
4. Discussion
The IGRPs are hydrophobic proteins, which share many of
the sequence characteristics of mammalian G6Pases, including
a phosphatase signature motif, and a C-terminal ER mem-
brane protein retention motif [6,7]. However, IGRP and the
G6Pases di¡er in their tissue speci¢city and physiological
functions. IGRP has a highly restricted expression pro¢le,
primarily limited to pancreatic L-cells [6,7], while G6Pase-K
is expressed in the gluconeogenic tissues, liver, kidney, and
intestine [1,2,27] and G6Pase-L [3^5] is ubiquitous. Further-
more, while both G6Pase-K and G6Pase-L possess a phospho-
hydrolase activity, IGRP has shown no enzymatic activity on
a variety of phosphorylated substrates, despite extensive study
[6,7]. G6Pase is a key enzyme in the regulation of interpran-
dial glucose homeostasis [8,9] and hepatic G6Pase expression
is elevated in human patients [28] and in rodent models of
non-insulin-dependent diabetes mellitus (NIDDM) [29,30].
Although it was speculated that G6Pase over-expression
may contribute to the pathophysiology of NIDDM, there
has not been any direct evidence linking G6Pase to diabetes.
It is therefore surprising that IGRP, an enzymatically inactive
member of the G6Pase family, has been identi¢ed as the
source of the natural peptide autoantigen targeted by a prev-
alent population of pathogenic CD8þ T cells in NOD mice
[10].
One explanation for the antigenicity and lack of phospho-
hydrolase activity of IGRP is that it is not processed in the
cell in the same manner as the G6Pases. To this end we have
examined the post-translational modi¢cation, subcellular lo-
calization and topography of IGRP.
Using immuno£uorescence microscopy, we have demon-
strated that IGRP co-localizes in cells with the ER marker
protein calreticulin [19], con¢rming that IGRP is an ER-asso-
ciated protein. Moreover, IGRP is a transmembrane protein.
Protease protection mapping clearly shows IGRP oriented
with the N-terminus facing into the lumen of the ER and
the C-terminus facing into the cellular cytoplasm, consistent
with an odd number of transmembrane domains and with the
orientation of G6Pase-K [13,14]. Theoretical modeling of the
topography of IGRP [21] predicts that IGRP is anchored in
the ER membrane by either seven or eight transmembrane
helices. If this is correct, a topographical di¡erence, splitting
the conserved active site residues of G6Pase between loops, or
placing them on the cytoplasmic side of the ER membrane in
IGRP could account for the lack of phosphohydrolase activity
in IGRP. However, this is not the case. By individually mu-
tating each of the three potential Asn-linked glycosylation
sites in IGRP we showed that only mutation of Asn92 changes
the natural electrophoretic pro¢le of the protein, identifying
Asn92 as the sole N-linked glycosylation site in vivo. Since
potential Asn-linked glycosylation sites are localized on the
luminal side of the ER membrane [22,23], N92HS must reside
on a luminal loop, which is inconsistent with the seven-trans-
membrane domain model, but supports the nine-transmem-
brane domain model for IGRP predicted by sequence align-
ment of the members of the G6Pase family.
The cellular immune response leading to diabetes in the
NOD mouse is executed by cytotoxic and helper T lympho-
cytes, which recognize small antigenic peptide fragments asso-
ciated with MHC class I molecules [18]. Most MHC-associ-
ated peptide antigens are generated from protein degradation
by the proteasomes [15^17] and consistent with this we ¢nd
that IGRP degradation is also proteasome-mediated, like
G6Pase-K [31]. The divergence between amino acids 206^
214, the source of the natural peptide antigen in IGRP and
the corresponding sequence in mammalian G6Pase may ex-
plain why G6Pase-K, processed by the same pathway, is not
presented to the immune system in an antigenic manner.
The lack of phosphohydrolase activity associated with
IGRP raises the question of the role of IGRP in vivo. Glucose
is the primary physiological stimulus for activation of insulin
gene transcription (reviewed in [32]). In pancreatic L-cells
G6Pase functionally antagonizes the glucokinase sensor activ-
ity, critical to glucose utilization and glucose-stimulated insu-
lin secretion [33]. Therefore, an active G6Pase within the pan-
creatic L-cells would be predicted to disrupt the expression of
insulin and contribute to diabetes. One possibility is that mul-
tiple mutations evolved to inactivate G6Pase activity and
avoid the disruption of insulin expression. Consistent with
Fig. 4. The e¡ect of proteasome inhibitor lactacystin on degradation
of IGRP. Two sets of COS-1 cells were transfected with the IGRP-
3FLAG construct. After 34 h incubation at 37‡C, 1 WM lactacystin
was added to one set of cultures and the incubation was continued
for an additional 14 h. The steady-state levels of IGRP protein on
the Western membrane were visualized by an anti-FLAG monoclo-
nal antibody; each lane contained 20 Wg proteins.
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this is the ¢nding that the rat IGRP gene contains a series of
deletions and insertions in the coding sequence, lacks a TATA
box in its promoter, and is not transcribed in rat islets [7]. In
human and mouse islets, IGRP is transcribed well but there
are several alternative spliced transcripts [6,7]. The full-length
mRNA was studied here because it encodes the protein most
similar to G6Pase-K, but it is not the most abundant tran-
script. The most abundant transcript is an exon-4-deleted
mRNA that encodes a truncated IGRP lacking the peptide
antigen at amino acids 206^214 and in an evolutionary sense
does not present a risk to the pancreatic L-cells [6,7]. It will be
of interest to determine if the ratio of full-length to truncated
IGRP mRNA di¡ers between normal and diabetes-susceptible
mammals.
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